This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
BDX Stock Gains Following Q4 Earnings Beat and Higher Margins
by Zacks Equity Research
BD's overall topline in the fourth quarter of fiscal 2024 benefits from revenue growth in all segments.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Becton Dickinson (BDX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Becton Dickinson (BDX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Becton Dickinson (BDX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 1.06% and 1.59%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy, Sell or Hold DENTSPLY SIRONA Before Q3 Earnings?
by Zacks Equity Research
XRAY's third-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.
Should You Buy, Sell or Hold McKesson Before Q2 Earnings?
by Zacks Equity Research
MCK's second-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
Can Sustained Product Demand Drive BDX Stock Before Q4 Earnings?
by Zacks Equity Research
Continued solid uptake of BD's products is expected to have driven fiscal fourth-quarter revenues.
Insights Into Becton Dickinson (BDX) Q4: Wall Street Projections for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Becton Dickinson (BDX) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
BDX Stock Declines Despite Launching BD IO Vascular Access System
by Zacks Equity Research
BD announces the BD Intraosseous Vascular Access System to enable quick vascular access for critical care situations.
Cardinal Health (CAH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 14.63% and 1.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Top Analyst Reports for Toyota, Texas Instruments & Arista Networks
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Toyota Motor Corporation (TM), Texas Instruments Incorporated (TXN) and Arista Networks, Inc. (ANET), as well as a micro-cap stock Crown Crafts, Inc. (CRWS).
Becton Dickinson (BDX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bear of the Day: Align Technology (ALGN)
by Jeremy Mullin
Will this stock find the right alignment to avoid further decline?
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Becton Dickinson (BDX) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Strong Segmental Performance to Drive Stryker's Q3 Earnings
by Zacks Equity Research
SYK's third-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Will Non-COVID-19 Diagnostics Sales Drive Hologic's Q4 Earnings?
by Zacks Equity Research
HOLX's fiscal 2024 fourth-quarter results are expected to reflect a solid performance of the Diagnostics business, led by the base Molecular franchise.
3 Reasons Why Becton Dickinson (BDX) Is a Great Growth Stock
by Zacks Equity Research
Becton Dickinson (BDX) possesses solid growth attributes, which could help it handily outperform the market.
BDX vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
BDX vs. MMSI: Which Stock Is the Better Value Option?
Will CGM Sensor Demand Continue to Drive DexCom Q3 Earnings?
by Zacks Equity Research
DXCM's third-quarter 2024 results are likely to reflect rising volumes across all channels.
What's in Store for West Pharmaceutical in Q3 Earnings?
by Zacks Equity Research
WST's third-quarter 2024 results are likely to reflect weakness in its Proprietary Products business. Unfavorable currency movements might have hurt the top and bottom lines.
Should You Buy, Sell or Hold HOLX Stock Ahead of Q4 Earnings?
by Moumi Mondal
Hologic's upcoming fourth-quarter fiscal 2024 financial report is expected to reflect strength in core franchises.
BDX Stock Up on Robotics Solution Launch to Boost Single-Cell Research
by Zacks Equity Research
BD aims to automate the complex library preparation process to aid researchers get consistent results and minimize the variability stemming from manual procedures.
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.